- Home
- TONX vs TLSA Comparison
TONX vs TLSA Comparison
Compare TONX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TONX | TLSA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | 23 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.5M | 155.2M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TONX | TLSA |
|---|---|---|
| Price | $2.66 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 361.6K | 111.1K |
| Earning Date | 05-12-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $526.82 | N/A |
| Revenue Next Year | $45.45 | N/A |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.73 |
| 52 Week High | $8.23 | $2.60 |
Technical Indicators
Market Signals| Indicator | TONX | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 43.60 |
| Support Level | $1.80 | N/A |
| Resistance Level | $3.61 | $1.56 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 23.66 | 22.25 |
Price Performance
Historical ComparisonAbout TONX TON Strategy Company
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.